Abdominal Distension News and Research

RSS

NPS announces new data from GATTEX Phase 3 study on short bowel syndrome

NPS Pharmaceuticals, Inc., a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, today announced new data from STEPS 2, a long-term open-label study, showing that GATTEX (teduglutide) was associated with achieving and maintaining clinically meaningful reductions in parenteral nutrition (PN) and intravenous (IV) fluid volume in adult subjects with short bowel syndrome.

1 Nov 2011

Double balloon enteroscopy safe and effective for detection of small intestine diseases

A large-scale data review by researchers in China of double balloon enteroscopy (DBE) over the last decade showed the endoscopic procedure to be safe and effective for detection of diseases of the small intestine.

27 Sep 2011

Irritable Bowel Syndrome linked to bacterial overgrowth, food poisoning

Cedars-Sinai researchers have reported two advances in the understanding of Irritable Bowel Syndrome, the most common gastrointestinal disorder in the United States, affecting an estimated 30 million people.

12 May 2011

Study: Antibiotics can provide long-lasting relief to patients with irritable bowel syndrome

A ground-breaking antibiotic therapy developed at Cedars-Sinai Medical Center is the first potential drug treatment to provide irritable bowel syndrome patients with long-lasting relief of their symptoms even after they stop taking the medication, according to a study published in the Jan. 6 issue of the New England Journal of Medicine.

6 Jan 2011

Long-term phase 3 trial confirms safety of lubiprostone in Japanese patients with chronic idiopathic constipation

Sucampo Pharmaceuticals, Inc. and Abbott today announced positive top-line data from a 48-week phase 3 long-term safety and efficacy clinical trial of lubiprostone in Japanese patients with chronic idiopathic constipation (CIC). The trial demonstrated that lubiprostone was safe and well-tolerated.

30 Nov 2010

Chongqing Cancer Hospital commences treatment with Varian's RapidArc radiotherapy

Chongqing Cancer Hospital in Southwest China has become the first treatment center in Southwest China to offer cancer patients a faster, more precise form of image-guided radiotherapy that potentially enables doctors to improve outcomes while extending more advanced care to more patients. Clinicians at the hospital have used RapidArc® radiotherapy from Varian Medical Systems to treat patients for cancers of the nasopharynx, cervix, breast, and lung.

11 Oct 2010

Gilead Sciences announces Quad regimen Phase II clinical trial results for HIV infection treatment

Gilead Sciences, Inc. today announced Phase II clinical trial results showing that its investigational fixed-dose, single-tablet "Quad" regimen of elvitegravir, cobicistat and Truvada (emtricitabine and tenofovir disoproxil fumarate) for the treatment of HIV infection maintained a high rate of virologic suppression through 48 weeks, exhibiting antiretroviral activity comparable to that of Atripla(efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg).

14 Sep 2010

Targeted antibiotics provide safe, long-lasting improvement for IBS patients, says study

A targeted antibiotic provides effective and long-lasting relief of Irritable Bowel Syndrome symptoms, according to the results of two multisite Phase III clinical trials designed by Cedars-Sinai researchers. Rifaximin is the first drug treatment for IBS that relieves symptoms while it's being administered and continues to benefit patients after they stop taking the drug.

5 May 2010

More than half of women with ovarian cancer face delay in diagnosis

Many women with ovarian cancer can go undiagnosed for months because their symptoms are not always being investigated promptly, warn researchers at the University of Bristol in a study published on bmj.com today.

26 Aug 2009

Cause and clinical outcome of portal vein thrombosis

Among the 118 patients with portal vein thrombosis, noncirrhotic and nontumoral extrahepatic portal vein obstruction are young and present with well tolerated bleed.

15 Oct 2007

FDA accepts Sucampo's sNDA for Lubiprostone for the treatment of irritable bowel syndrome

Sucampo Pharmaceuticals, Inc., has announced that the supplemental New Drug Application (sNDA) for lubiprostone (8 mcg, oral gel capsules, twice daily) for the treatment of irritable bowel syndrome with constipation (IBS-C) has been accepted for review by the U.S. Food and Drug Administration (FDA).

18 Sep 2007

NDA for Lubiprostone to treat irritable bowel syndrome with constipation

Sucampo Pharmaceuticals, Inc., has announced that it has submitted a supplemental New Drug Application to the U.S. Food and Drug Administration to seek market approval of a lower strength of lubiprostone (8 mcg) to treat irritable bowel syndrome with constipation (IBS-C).

13 Jul 2007

FDA warns on health risks of potentially contaminated Olives

The U.S. Food and Drug Administration (FDA) is alerting consumers to possible serious health risks from eating olives that may be contaminated with a deadly bacterium, Clostridium botulinum . C. botulinum can cause botulism, a potentially fatal illness.

14 Apr 2007

Canadians paralysed after drinking carrot juice

Carrot juice which was withdrawn from the market late last month is thought to be responsible for the illness of two Canadians who are paralyzed and are severely ill in hospital.

9 Oct 2006

Many lives may be saved by new blood test for ovarian cancer

A new blood test which has the potential to save many lives has been developed to detect ovarian cancer, a disease known as the silent killer because it is so difficult to identify.

9 May 2005